Redhill Biopharma Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.82
- Today's High:
- $0.8598
- Open Price:
- $0.8598
- 52W Low:
- $0.795
- 52W High:
- $38.4
- Prev. Close:
- $0.84
- Volume:
- 46710
Company Statistics
- Market Cap.:
- $4.91 million
- Book Value:
- 1.086
- Revenue TTM:
- $35.75 million
- Operating Margin TTM:
- -78.01%
- Gross Profit TTM:
- $45.25 million
- Profit Margin:
- 32.37%
- Return on Assets TTM:
- -17.17%
- Return on Equity TTM:
- -884.29%
Company Profile
Redhill Biopharma Ltd had its IPO on 2013-01-07 under the ticker symbol RDHL.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Redhill Biopharma Ltd has a staff strength of 113 employees.
Stock update
Shares of Redhill Biopharma Ltd opened at $0.86 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.82 - $0.86, and closed at $0.86.
This is a +1.79% increase from the previous day's closing price.
A total volume of 46,710 shares were traded at the close of the day’s session.
In the last one week, shares of Redhill Biopharma Ltd have slipped by -2.73%.
Redhill Biopharma Ltd's Key Ratios
Redhill Biopharma Ltd has a market cap of $4.91 million, indicating a price to book ratio of 4.6005 and a price to sales ratio of 0.2159.
In the last 12-months Redhill Biopharma Ltd’s revenue was $35.75 million with a gross profit of $45.25 million and an EBITDA of $-24068000. The EBITDA ratio measures Redhill Biopharma Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Redhill Biopharma Ltd’s operating margin was -78.01% while its return on assets stood at -17.17% with a return of equity of -884.29%.
In Q2, Redhill Biopharma Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a negative 90.2%.
Redhill Biopharma Ltd’s PE and PEG Ratio
- Forward PE
- 1428.5714
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-7.81 per share while it has a forward price to earnings multiple of 1428.5714 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Redhill Biopharma Ltd’s profitability.
Redhill Biopharma Ltd stock is trading at a EV to sales ratio of 1.7286 and a EV to EBITDA ratio of -3.9033. Its price to sales ratio in the trailing 12-months stood at 0.2159.
Redhill Biopharma Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $35.04 million
- Total Liabilities
- $28.19 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $7000
- Dividend Payout Ratio
- 0%
Redhill Biopharma Ltd ended 2024 with $35.04 million in total assets and $0 in total liabilities. Its intangible assets were valued at $35.04 million while shareholder equity stood at $3.47 million.
Redhill Biopharma Ltd ended 2024 with $0 in deferred long-term liabilities, $28.19 million in other current liabilities, 4620000.00 in common stock, $-382009000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $7.00 million and cash and short-term investments were $7.01 million. The company’s total short-term debt was $1,290,000 while long-term debt stood at $0.
Redhill Biopharma Ltd’s total current assets stands at $27.05 million while long-term investments were $0 and short-term investments were $18000.00. Its net receivables were $5.95 million compared to accounts payable of $3.11 million and inventory worth $4.94 million.
In 2024, Redhill Biopharma Ltd's operating cash flow was $0 while its capital expenditure stood at $7000.
Comparatively, Redhill Biopharma Ltd paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.86
- 52-Week High
- $38.4
- 52-Week Low
- $0.795
- Analyst Target Price
- $40
Redhill Biopharma Ltd stock is currently trading at $0.86 per share. It touched a 52-week high of $38.4 and a 52-week low of $38.4. Analysts tracking the stock have a 12-month average target price of $40.
Its 50-day moving average was $1.13 and 200-day moving average was $4.54 The short ratio stood at 0.02 indicating a short percent outstanding of 0%.
Around 437% of the company’s stock are held by insiders while 1111.4% are held by institutions.
Frequently Asked Questions About Redhill Biopharma Ltd
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn’s disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.